IFNGR1 and Hepatic fibrosis: In the present study, we have directed IFNγ or mimetic IFNγ (signaling moiety of IFNγ lacking extracellular IFNγR binding site while retaining activities of IFNγ) [33] to PDGFβR-expressing activated HSC using bicyclic PDGFβR peptides to inhibit liver fibrosis with reduced adverse effects.